Biogen
BIIB
1,036 hedge funds and large institutions have $30.7B invested in Biogen in 2026 Q2 according to their latest regulatory filings, with 125 funds opening new positions, 423 increasing their positions, 292 reducing their positions, and 82 closing their positions.
52% more first-time investments, than exits
New positions opened: 125 | Existing positions closed: 82
45% more repeat investments, than reductions
Existing positions increased: 423 | Existing positions reduced: 292
43% more call options, than puts
Call options by funds: $676M | Put options by funds: $473M
24% more capital invested
Capital invested by funds: $24.7B → $30.7B (+$5.92B)
14% more funds holding in top 10
Funds holding in top 10: 7 → 8 (+1)
4.24% more ownership
Funds ownership: 91.95% → 96.19% (+4.2%)
3% more funds holding
Funds holding: 1,009 → 1,036 (+27)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$1.03B |
| 2 |
Amundi
Paris,
France
|
+$139M |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$96.9M |
| 4 |
Pacer Advisors
Malvern,
Pennsylvania
|
+$88.5M |
| 5 |
Primecap Management
Pasadena,
California
|
+$75.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
-$200M |
| 2 |
VanEck Associates
New York
|
-$188M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
-$138M |
| 4 |
Boston Partners
Boston,
Massachusetts
|
-$83.5M |
| 5 |
Balyasny Asset Management
Chicago,
Illinois
|
-$73.6M |
BIIB Hedge Fund Activity: Q2 2026 in Review
1,036 of the 8,279 institutional investors tracked by Wall St. Rank reported a position in Biogen (BIIB) for Q2 2026, worth a combined $30.7B — up 24% from $24.7B a quarter earlier.
Buyers outnumbered sellers: 125 funds opened new BIIB positions and 82 closed out — a net gain of 43 holders — while 423 added to existing stakes and 292 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $1.03B. The largest seller was T. Rowe Price Investment Management, cutting an estimated $200M.
- 1,036 institutional investors held Biogen (BIIB) as of Q2 2026, up from 1,009 in Q1 2026.
- Funds reported $30.7B of Biogen stock for Q2 2026, up 24% quarter-over-quarter.
- 125 funds opened new Biogen positions in Q2 2026 and 82 closed out, a net change of +43 holders.
- The largest Biogen buyer in Q2 2026 was Fidelity Investments, an estimated $1.03B added.
- The largest Biogen seller in Q2 2026 was T. Rowe Price Investment Management, an estimated $200M sold.
Based on aggregated 13F filings for Q2 2026.